We would love to hear your thoughts about our site and services, please take our survey here.
Need to detect it first.
https://www.dailystar.co.uk/health/breakthrough-prostate-cancer-treatment-nhs-31596366
Apologies if posted before.
Suppose you have a test that has 100% sensitivity but only 50% specificity. Then, assuming 1% actually have cancer, your test positives are 10k plus 495k. It's no use for screening, but this test has specificity of 97%. It's useful for mass screening and would save a lot of money in late cancer treatments
I've not seen anyone mention this, but the true value of this test is not in its high sensitivity. It's the high specificity of 97% that makes this worth billions. A high sensitivity is only useful for suspected cancer., but a high specificity allows routine screening.
E.g. 1 million men over 50 are tested. With a specificity of 97% 970,000 of them can be eliminated from further expensive screening.
Treeshake. I've been watching the trades. Consistantly at or even above the offer.
Just about every man above 50 will want this test annually. Another up day today is baked in, methinks. Ready to add on any significant drop though.
I get the same 'feelin'. Tho, I'm not quite sure what it means. Have they cracked it, or not? From the the RNS, it sounds like they haven't, and have just found a way of speeding the 'cracking' process. Looking forward to some info here.
Thanks for those replies. Yes, the dilution is significant and ongoing. Any opinions as to why Artemic isn't listed on their website? The website itself doesn't inspire my confidence tbh, but lack of their leading product is downright odd.
I would appreciate an answer to this also. And yes, I am a new (potential) investor.
Also, why the steady drop in SP? Seems they are making good progress from the RNS's. (I've been thru them all)
I say! Our Deidre is a bit hot.
FDS snowed under?
https://www.londonstockexchange.com/news-article/GSK/extension-of-fda-review-period-for-momelotinib/16001854
Looks promising. Took a small stake here.
So, 38% sensitivity and 46% specificity. CIZ is in the 90's for both.
Seems excellent ( I had to google it)
Negative predictive value:
It is the ratio of subjects truly diagnosed as negative to all those who had negative test results (including patients who were incorrectly diagnosed as healthy). This characteristic can predict how likely it is for someone to truly be healthy, in case of a negative test result.
They've been on AIM for years and just as they're turning the corner they've had enough?
If they were looking for debt, they'd have done it before now - last year it was clear borrowing conditions were tightening.
Lots of MA activity going on as the big boys swallow the minnows, led by the banks.
A sale would be the only viable option. Maybe they've already been approached.
I'll hold. An offer of £50m 1-bags us from here.
One hole, a mine does not make, but wow. Just wow!
He has 371k followers on Twitter!
Nice rise today :)
Just curious, did anyone look into my tip and buy in? Up 37% today on expansion into California against stiff opposition. Mental health gonna be a huge issue going forward methinks.
I have a share tip I'm willing to share - FOR YOUR OWN RESEARCH - NOT A RECOMMENDATION.
It's similar to CIZ in that it provides early intervention to a dire, and growing, health problem, that's cost-effective. I'll post it up if I get 10 recommendations for this post. It's about profit and helping people too.
Please keep comments polite if you're against.
Disclosure, yes I am a holder of CIZ and building a stake in the other.
TW, yeah I get that. Doesn't change my view that if IND was imminent the company would have been wiser to wait a few weeks to raise at a better price. Because of this, I'm sitting back for a wait and possibly a top-up in a month or so.
I am expecting (and prepared for) a prolonged delay in the RNS. We just had an (unnecessary) fundraise, which would be odd timing if positive news was imminent.
I'm surprised no one has flagged this yet.